Global Site License: US$ 875.00
Introduction
This databook provides key data and information on the Other OTC Healthcare Products Market in France (OTC Healthcare). This report is a comprehensive resource for market, category and segment level data including value, volume, distribution share and company & brand share. This report also provides expenditure and consumption data for the historic and forecast periods.
Scope
The other OTC healthcare products category was valued at €381.9m ($559.4m) in 2009, representing a CAGR of 5.1% since 2004.
By the end of 2014, the other OTC healthcare products category will be worth €463m ($678.2m), with an expected CAGR of 3.9% between 2009 and 2014.
The other OTC healthcare products market was led by anti-smoking aids (representing 37.2% of the total value) followed by eye / ear drops and rectal medications, with a 31% and 14.7% market share, respectively. Sleeping aids and motion sickness constitute the remaining segments with a 13.2% and 4% market share, respectively.
GlaxoSmithKline Plc is the market leader with a 16.2% share of the market
Reasons to Purchase
Introduction
This databook provides key data and information on the Other OTC Healthcare Products Market in France (OTC Healthcare). This report is a comprehensive resource for market, category and segment level data including value, volume, distribution share and company & brand share. This report also provides expenditure and consumption data for the historic and forecast periods.
Scope
- Market,category and segment level information on value, volume, and expenditure & consumption, with historic (2003-2008) and forecast (2009-2013) data
- Category level company and brand share as well as distribution share information for 2007 and 2008
The other OTC healthcare products category was valued at €381.9m ($559.4m) in 2009, representing a CAGR of 5.1% since 2004.
By the end of 2014, the other OTC healthcare products category will be worth €463m ($678.2m), with an expected CAGR of 3.9% between 2009 and 2014.
The other OTC healthcare products market was led by anti-smoking aids (representing 37.2% of the total value) followed by eye / ear drops and rectal medications, with a 31% and 14.7% market share, respectively. Sleeping aids and motion sickness constitute the remaining segments with a 13.2% and 4% market share, respectively.
GlaxoSmithKline Plc is the market leader with a 16.2% share of the market
Reasons to Purchase
- Develop business strategies by understanding the quantitative trends within the Other OTC Healthcare Products Market in France (OTC Healthcare)
- Design effective marketing and sales strategies by identifying key market categories and segments
- Identify key players within the market to plan lucrative M&A, partnerships and agreements
CHAPTER 1 EXECUTIVE SUMMARY
Summary category level: other OTC healthcare products
CHAPTER 2 DEFINITION
CHAPTER 3 CATEGORY ANALYSIS: OTHER OTC HEALTHCARE PRODUCTS
Value analysis (Euro), 2004−09
Value analysis (Euro), 2009−14
Value analysis (US dollars), 2004−09
Value analysis (US dollars), 2009−14
Company and brand share analysis
Distribution analysis
CHAPTER 4 MACROECONOMIC PROFILE
Macroeconomic indicators
CHAPTER 5 RESEARCH METHODOLOGY
Methodology overview
Secondary research
Market modeling
Creating an initial data model
Revising the initial data model
Creating a final estimate
Creating demographic value splits
Primary research
Data finalization
Ongoing research
LIST OF FIGURES
Figure 1: Other OTC healthcare products, France, value by segment (€m), 2004−14
Figure 2: Other OTC healthcare products, France, category growth comparison, by value, 2004−14
Figure 3: Other OTC healthcare products, France, company share by value (%), 2008−09
Figure 4: Other OTC healthcare products, France, distribution channels by value (%), 2008−09
Figure 5: Annual data review process
LIST OF TABLES
Table 1: Other OTC health care products category definitions
Table 2: Other OTC health care products distribution channels
Table 3: Other OTC healthcare products, France, value by segment (€m), 2004−09
Table 4: Other OTC healthcare products, France, value forecast by segment (€m), 2009−14
Table 5: Other OTC healthcare products, France, value by segment ($m), 2004−09
Table 6: Other OTC healthcare products, France, value forecast by segment ($m), 2009−14
Table 7: Other OTC healthcare products, France, brand share by value (%), 2008−09
Table 8: Other OTC healthcare products, France, value by brand (€m), 2008−09
Table 9: Other OTC healthcare products, France, company share by value (%), 2008−09
Table 10: Other OTC healthcare products, France, value by company (€m), 2008−09
Table 11: Other OTC healthcare products, France, distribution channels by value (%), 2008−09
Table 12: Other OTC healthcare products, France, value by distribution channel (€m), 2008−09
Table 13: France population, by age group, 2004−09 (millions)
Table 14: France population forecast, by age group, 2009−14 (millions)
Table 15: France population, by gender, 2004−09 (millions)
Table 16: France population forecast, by gender, 2009−14 (millions)
Table 17: France nominal GDP, 2004−09 (€bn, nominal prices)
Table 18: France nominal GDP forecast, 2009−14 (€bn, nominal prices)
Table 19: France real GDP, 2004−09 (€bn, 2000 prices)
Table 20: France real GDP forecast, 2009−14 (€bn, 2000 prices)
Table 21: France real GDP, 2004−09 ($bn, 2000 prices)
Table 22: France real GDP forecast, 2009−14 ($bn, 2000 prices)
Table 23: France consumer price index, 2004−09 (2000=100)
Table 24: France consumer price index, 2009−14 (2000=100)
Summary category level: other OTC healthcare products
CHAPTER 2 DEFINITION
CHAPTER 3 CATEGORY ANALYSIS: OTHER OTC HEALTHCARE PRODUCTS
Value analysis (Euro), 2004−09
Value analysis (Euro), 2009−14
Value analysis (US dollars), 2004−09
Value analysis (US dollars), 2009−14
Company and brand share analysis
Distribution analysis
CHAPTER 4 MACROECONOMIC PROFILE
Macroeconomic indicators
CHAPTER 5 RESEARCH METHODOLOGY
Methodology overview
Secondary research
Market modeling
Creating an initial data model
Revising the initial data model
Creating a final estimate
Creating demographic value splits
Primary research
Data finalization
Ongoing research
LIST OF FIGURES
Figure 1: Other OTC healthcare products, France, value by segment (€m), 2004−14
Figure 2: Other OTC healthcare products, France, category growth comparison, by value, 2004−14
Figure 3: Other OTC healthcare products, France, company share by value (%), 2008−09
Figure 4: Other OTC healthcare products, France, distribution channels by value (%), 2008−09
Figure 5: Annual data review process
LIST OF TABLES
Table 1: Other OTC health care products category definitions
Table 2: Other OTC health care products distribution channels
Table 3: Other OTC healthcare products, France, value by segment (€m), 2004−09
Table 4: Other OTC healthcare products, France, value forecast by segment (€m), 2009−14
Table 5: Other OTC healthcare products, France, value by segment ($m), 2004−09
Table 6: Other OTC healthcare products, France, value forecast by segment ($m), 2009−14
Table 7: Other OTC healthcare products, France, brand share by value (%), 2008−09
Table 8: Other OTC healthcare products, France, value by brand (€m), 2008−09
Table 9: Other OTC healthcare products, France, company share by value (%), 2008−09
Table 10: Other OTC healthcare products, France, value by company (€m), 2008−09
Table 11: Other OTC healthcare products, France, distribution channels by value (%), 2008−09
Table 12: Other OTC healthcare products, France, value by distribution channel (€m), 2008−09
Table 13: France population, by age group, 2004−09 (millions)
Table 14: France population forecast, by age group, 2009−14 (millions)
Table 15: France population, by gender, 2004−09 (millions)
Table 16: France population forecast, by gender, 2009−14 (millions)
Table 17: France nominal GDP, 2004−09 (€bn, nominal prices)
Table 18: France nominal GDP forecast, 2009−14 (€bn, nominal prices)
Table 19: France real GDP, 2004−09 (€bn, 2000 prices)
Table 20: France real GDP forecast, 2009−14 (€bn, 2000 prices)
Table 21: France real GDP, 2004−09 ($bn, 2000 prices)
Table 22: France real GDP forecast, 2009−14 ($bn, 2000 prices)
Table 23: France consumer price index, 2004−09 (2000=100)
Table 24: France consumer price index, 2009−14 (2000=100)
